Switch theme
Sign up to access all valuation multiples
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
2004
185
LTM Revenue $39.8M
LTM EBITDA -$4.5M
$93.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Myomo has a last 12-month revenue (LTM) of $39.8M and a last 12-month EBITDA of -$4.5M.
In the most recent fiscal year, Myomo achieved revenue of $32.6M and an EBITDA of -$5.4M.
Myomo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Myomo valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $39.8M | XXX | $32.6M | XXX | XXX | XXX |
| Gross Profit | $28.1M | XXX | $23.2M | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | -$4.5M | XXX | -$5.4M | XXX | XXX | XXX |
| EBITDA Margin | -11% | XXX | -17% | XXX | XXX | XXX |
| EBIT | -$6.3M | XXX | -$6.2M | XXX | XXX | XXX |
| EBIT Margin | -16% | XXX | -19% | XXX | XXX | XXX |
| Net Profit | -$6.3M | XXX | -$6.2M | XXX | XXX | XXX |
| Net Margin | -16% | XXX | -19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Myomo's stock price is $3.
Myomo has current market cap of $107M, and EV of $93.6M.
See Myomo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $93.6M | $107M | XXX | XXX | XXX | XXX | $-0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Myomo has market cap of $107M and EV of $93.6M.
Myomo's trades at 2.9x EV/Revenue multiple, and -17.2x EV/EBITDA.
Equity research analysts estimate Myomo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Myomo has a P/E ratio of -17.0x.
See valuation multiples for Myomo and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $107M | XXX | $107M | XXX | XXX | XXX |
| EV (current) | $93.6M | XXX | $93.6M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | -20.6x | XXX | -17.2x | XXX | XXX | XXX |
| EV/EBIT | -14.8x | XXX | -15.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -17.0x | XXX | -17.3x | XXX | XXX | XXX |
| EV/FCF | -16.4x | XXX | -20.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMyomo's last 12 month revenue growth is 40%
Myomo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Myomo's rule of 40 is 0% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Myomo's rule of X is 89% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Myomo and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 40% | XXX | 40% | XXX | XXX | XXX |
| EBITDA Margin | -11% | XXX | -17% | XXX | XXX | XXX |
| EBITDA Growth | -90% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 0% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 89% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 90% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Senseonics Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Myomo acquired XXX companies to date.
Last acquisition by Myomo was XXXXXXXX, XXXXX XXXXX XXXXXX . Myomo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Myomo founded? | Myomo was founded in 2004. |
| Where is Myomo headquartered? | Myomo is headquartered in United States of America. |
| How many employees does Myomo have? | As of today, Myomo has 185 employees. |
| Who is the CEO of Myomo? | Myomo's CEO is Mr. Paul R. Gudonis. |
| Is Myomo publicy listed? | Yes, Myomo is a public company listed on ASE. |
| What is the stock symbol of Myomo? | Myomo trades under MYO ticker. |
| When did Myomo go public? | Myomo went public in 2017. |
| Who are competitors of Myomo? | Similar companies to Myomo include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Myomo? | Myomo's current market cap is $107M |
| What is the current revenue of Myomo? | Myomo's last 12 months revenue is $39.8M. |
| What is the current revenue growth of Myomo? | Myomo revenue growth (NTM/LTM) is 40%. |
| What is the current EV/Revenue multiple of Myomo? | Current revenue multiple of Myomo is 2.4x. |
| Is Myomo profitable? | Yes, Myomo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Myomo? | Myomo's last 12 months EBITDA is -$4.5M. |
| What is Myomo's EBITDA margin? | Myomo's last 12 months EBITDA margin is -11%. |
| What is the current EV/EBITDA multiple of Myomo? | Current EBITDA multiple of Myomo is -20.6x. |
| What is the current FCF of Myomo? | Myomo's last 12 months FCF is -$5.7M. |
| What is Myomo's FCF margin? | Myomo's last 12 months FCF margin is -14%. |
| What is the current EV/FCF multiple of Myomo? | Current FCF multiple of Myomo is -16.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
